Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets
Swedish Orphan Biovitrum and Dongbao announced their intent to form a strategic Commercial Alliance. In such an alliance, Swedish Orphan Biovitrum would be the marketing and sales partner of choice for Dongbao's pipeline of biopharmaceuticals and other drugs in Europe and Dongbao would be the marketing and sales partner of choice for Swedish Orphan Biovitrum's marketed and pipeline products in China.
The announced Commercial Alliance would be a partnership where both parties will benefit in two ways. First, each party secures a marketing and sales partner for its own products in an important new territory, China in the case of Swedish Orphan Biovitrum and Europe in the case of Dongbao. Second, each party gains access to a new portfolio of exciting products for its home markets.
Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated "We are very pleased to have identified a partner in Dongbao with a successful track record of selling high value biotechnology products in China. Dongbao has a deep understanding of biotechnology products from a manufacturing and clinical development perspective. Moreover, they have an impressive track record of success in regulatory affairs as well as in marketing and sales. Thus, we see Dongbao as the perfect partner to help Swedish Orphan Biovitrum to realize the significant opportunity for our products in the Chinese market.
Other news from the department business & finance
